-
Mashup Score: 0
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 29
PURPOSE A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. METHODS Patients with either MRD (≥1 log10 rise) or oligoblastic relapse (blasts 5%-15%) received venetoclax 600 mg once daily D1-28 plus LDAC once daily D1-10 in 28-day cycles. The primary objective was MRD response in the MRD relapse cohort or complete remission (CR/CRh/CRi) in the oligoblastic relapse cohort. RESULTS Forty-eight adults with either MRD (n = 26) or oligoblastic (n = 22) relapse were enrolled. Median age was 67 years (range, 18-80) and 94% had received previous intensive chemotherapy. Patients received a median of four cycles of therapy; 17% completed ≥12 cycles. Patients with oligoblastic relapse had more grade ≥3 anemia (32% v 4%; P = .02) and infections (36% v 8%; P = .03), whereas grade 4 neutropenia (32 v 23%) or thrombocytopenia (27 v 15%) were comparable with the MR
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 22
Neoantigens arising from recurrent AML mutations are immunogenic and represent novel immunotherapeutic targets.IDH2R140Q-specific T cells can selectively e
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies - 7 day(s) ago
Nicosia et al. find that CCS1477 (inobrodib), an EP300/CBP bromodomain inhibitor, induces cell-cycle arrest and differentiation in hematologic malignancy models through disrupting EP300/CBP recruitment to enhancer networks occupied by critical transcription factors. In patients with relapsed/refractory disease, CCS1477 monotherapy induces differentiation responses in AML and objective responses in myeloma.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Adults With Acute Myeloid Leukemia Follow One of Four Trajectories of Physical Well-Being | ASH Clinical News | American Society of Hematology - 12 day(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago. New results indicate that while many adults with acute myeloid leukemia (AML) experience some decline in physical health, patients can be grouped into four distinct trajectories of physical well-being (PWB). Marielle Jensen-Battaglia, PT, DPT, a licensed physical therapist and epidemiology PhD candidate at the University of Rochester Medical Center in New York, and colleagues published the results of the first study to explore risk factors
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 40
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Transplant without salvage: cut out the middleman - 20 day(s) ago
In this issue of The Lancet Haematology, Matthias Stelljes and colleagues1 present a compelling exploration of an approach to allogeneic haematopoietic stem-cell transplantation (HSCT) in patients at high risk of relapse or induction-refractory acute myeloid leukaemia. This concept is in stark contrast with the long-upheld orthodoxy of using varying regimens of salvage chemotherapy to induce remission or a morphological leukaemia-free state before transplantation.2 These approaches, while considered to be the standard of care in most institutions, are associated with substantial morbidity, particularly when conventional chemotherapy is used.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
.@us_fda Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML #leusm https://t.co/g554JT9Hq4